Literature DB >> 15340698

[Recommendations for statin therapy in the elderly].

S Döser1, W März, M-F Reinecke, P Ringleb, A Schultz, P Schwandt, H J Becker, G Bönner, M Buerke, H C Diener, H Gohlke, U Keil, E B Ringelstein, A Steinmetz, R Gladisch, M Wehling.   

Abstract

Elderly patients are significantly less likely to receive statins than younger patients possibly because of doubts regarding compliance or concerns regarding the increased likelihood of adverse events and drug interactions. Poor compliance can be expected especially in patients suffering from dementia or depression as well as those whose stage of cardiovascular disease exhibits few symptoms. On the other hand, the clinical significance of CHD events is high in the elderly, and 80% of coronary deaths occur in patients aged over 65 years. The average statistical life expectancy of elderly and old patients is often underestimated. The HPS and PROSPER studies showed that statins reduce mortality and morbidity even in very elderly individuals with a high global cardiovascular risk and/or CAD. Patients up to the age of 79 years should be treated according to the same guidelines as younger patients. Statin therapy should only be considered for patients aged 80 years and older who are at a very high risk for cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340698     DOI: 10.1007/s00108-004-1268-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  33 in total

1.  Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.

Authors:  J S Schwartz
Journal:  Am Heart J       Date:  1999-05       Impact factor: 4.749

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

4.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 5.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

Authors: 
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

Review 8.  The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women.

Authors:  William B Kannel
Journal:  J Gend Specif Med       Date:  2002 Mar-Apr

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.

Authors:  Ian Ford; Gerard Jan Blauw; Michael B Murphy; James Shepherd; Stuart M Cobbe; Edward LEM Bollen; Brendan M Buckley; J Wouter Jukema; Michael Hyland; Allan Gaw; A Margot Lagaay; Ivan J Perry; Peter Macfarlane; John Norrie; A Edo Meinders; Brian J Sweeney; Chris J Packard; Rudi GJ Westendorp; Cillian Twomey; David J Stott
Journal:  Curr Control Trials Cardiovasc Med       Date:  2002-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.